MPM Oncology Impact Management as of June 30, 2020
Portfolio Holdings for MPM Oncology Impact Management
MPM Oncology Impact Management holds 11 positions in its portfolio as reported in the June 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Repare Therapeutics Common (RPTX) | 19.7 | $74M | 2.4M | 31.02 | |
| Harpoon Therapeutics Common | 17.2 | $65M | 3.9M | 16.60 | |
| TCR2 Therapeutics Common | 13.8 | $52M | 3.4M | 15.36 | |
| MEI Pharma Common | 11.1 | $42M | 10M | 4.13 | |
| Epizyme Common | 10.0 | $37M | 2.3M | 16.06 | |
| G1 Therapeutics Common | 9.2 | $35M | 1.4M | 24.26 | |
| ADC Therapeutics Common (ADCT) | 6.7 | $25M | 540k | 46.81 | |
| Turning Point Therapeutics Common | 5.3 | $20M | 309k | 64.59 | |
| YmAbs Therapeutics Common (YMAB) | 3.9 | $15M | 337k | 43.20 | |
| Merus Common (MRUS) | 3.0 | $11M | 701k | 16.09 | |
| Autolus Therapeutics Common (AUTL) | 0.2 | $637k | 40k | 16.03 |
